Phân tích proteomic mô gan của người bị ung thư gan nguyên phát

KIẾN NGHỊ

1. Tiếp tục thu thập mẫu và phân tích proteomics mô gan của bệnh nhân ung thư gan do các nguyên nhân khác nhau và các giai đoạn ung thư khác nhau nhằm phân tích sự biến đổi thành phần các protein liên quan đến bệnh.

2. Thu thập mẫu huyết tương của bệnh nhân viêm gan B và C đang tiến triển thành ung thư gan và bệnh nhân ung thư gan có tiền sử nhiễm HBV và HCV nhằm tìm hiểu mối liên hệ giữa viêm gan B, C và ung thư gan.

3. Kết hợp phân tích proteomics huyết tương và mô gan để tìm ra mối liên hệ giữa hai hệ protein này, nhằm tìm ra các chỉ thị ung thư gan đặc hiệu và dễ dàng nhận biết, phục vụ cho chẩn đoán sớm ung thư gan.

1. 
   Phan Văn Chi (2006), PROTEOMICS Khoa học về hệ gene, Viện Khoa học và Công nghệ Việt Nam, Hà Nội.
   
2. 
   Đỗ Ngọc Liên (2004), Miễn dịch học cơ sở, NXB Đại học Quốc gia Hà Nội.
   
3. 
   Hà Văn Mạo, Hoàng Kỷ, Phạm Hoàng Phiệt (2006), Ung thư gan nguyên phát, Nhà xuất bản y học.
   
4. 
   Vũ Minh Thiết, Nguyễn Nam Long, Đặng Thành Nam (2004), “Ngiên cứu hệ proteomic huyết thanh người bằng kết nối sắc ký lỏng Nano đa chiều và hệ khối phổ liên tục”, Báo cáo khoa học hội nghị toàn quốc 2004, [16] NCCB định hướng Y-Dược học, Học viện Quân Y, Hà Nội, tr. 470-474.
   

5. 
   Aderson, M.P,. A.N.L.(2006), "A List of Candidate Cancer Biomarker for Targeted Proteomics", Bio Ins, 1, PP. 1–48.
   
6. 
   Amy J. Clippinger and Michael J. Bouchard (2008), “Hepatitis B Virus HBx Protein Localizes to Mitochondria in Primary Rat Hepatocytes and Modulates Mitochondrial Membrane Potential”, J Virology, 82 (14), PP. 6798-6811.
   
7. 
   Andries K. V., Guillemont J, Winkler H, Van Gestel (2005), “A diaryquinolime drug active on the ATP synthase of Mycobacterium tuberculosis”, Science, 307 (7), PP. 223-227.
   
8. 
   Brachmann R. K. , Vidal M. & Boeke J. D. (1996): “Dominant-negative p53 mutations selected in yeast hit cancer hot spots”, Proc Natl Acad Sci. USA, 93, PP. 4091-5000.
   
9. 
   Bakos A.D, Hutson S.P, (2008), “BRCA mutation-negative women from hereditary breast and overian cancer families: a qualitative study of the BRCA-negative experience”, NIH, 11(3), PP. 205-207.
   
10. 
    Deng-Fu Yao, Z.Z.D.A.M.Y. (2007), “Specific molecular marker in hepatocellular carcinoma”, Science, 6(3), PP. 241-247.
    
11. 
    Shahid a Khan (2009), “Diagnosis of hepatocellular carcinoma” World J Gastroenterol, 15(11), PP. 1301-1314.
    
12. 
    Nguyen Minh Đuc, Nguyen Thi Ngoc Ha, Trinh Hong Thai, (2009), “Proteomic analysis of bone marrow cells from leukemia patients”, Proceedings of the National Conference on Proteomics, April 01-02 , 2009 in Do Son, p.65-78.
    
13. 
    Farazi P.A., Depinho R.A, (2006), “Hepatocelular carcinoma phathogenses: from genes to evironment”, Nat Rev Cancer, 6, PP. 674-687.
    
14. 
    Govekar R.B. And Zingde S.M, (2007), "Cancer Proteomics: How Far are We from Clinics" Int J Hum Genet, 7(1), PP. 91-97.
    
15. 
    Harris C. C (1996), “Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies”. JNCI, 88, PP. 1442-1455.
    
16. 
    He M., Zhai R., Wei X., Wang Q., Jiang M. R. Z., Huang Y., and Zhang Z, (2008), “Detection and identification of NAP-2 as a biomarker in hepatitis B-related hepatocellular carcinoma by proteomic approach”, Pro Sci, 6, PP. 1-11.
    
17. 
    Huong T. T. T., Thai T. H. (2006), “Plasma proteomic analysis of acute myeloid leukemia”, Program & Abstracts Joint Third AOHUPO and Fourth Structural Biology and Functional Genomics Conference, PP. 250.
    
18. 
    Jain K., M.D., Fracs, Ffpm, (2002, "Role of Proteomics in Diagnosis of Cancer", Tech Cancer Res & Treatt, 1(4), PP.281-286.
    
19. 
    Jesus M. Matos, Frank A. Witzmann,(2009), “A Pilot Study of Proteomic Profiles of Human Hepatocellular Carcinoma in the United States”, J Surg Res, 155(2), PP. 237–243.
    
20. 
    Jennifer S Carew and Peng Huang (2002), “Mitochondrial defects in cancer”, Mole Cancer, 9, PP. 1476-4598.
    
21. 
    Kim W., L.S.O., Kim J. S., Ryu Y. H., Byeon J., Kim H, Kim Y., Heo J. S., Park Y. M., and Jung G, (2003), “Comparison of Proteome between Hepatitis B Virus- and Hepatitis C Virus-Associated Hepatocellular Carcinoma”, Clinl Cancer Res, 9, PP. 5493–5500.
    
22. 
    K. Nakamura, X.Z., M. Fujimoto, T. Tanaka, J. Kimura-Akada, H.Furumoto, Y. Kuramitsu, B. Jordan, (2008), “1D-SDS-PAGE and Nano-LC-MS/MS for Membrane Proteomics of Mouse Liver Microsomes (MPI sample) and its Application to Human Proteomics of ER from Jurkat Cells”, J Pro & Bio, S2, PP.114-115.
    
23. 
    Kondo T.(2008), “Tissue proteomics for cancer biomarker development Laser micro dissection and 2D-DIGE”, PP. 5493-5500.
    
24. 
    Lane S., William, (2007), “Comparative Cytochrome P450 Proteomics in the Livers of Immunodeficient Mice Using ¹⁸O Stable Isotope Labeling”, Mole Cell Bio, 6, PP. 953-962.
    
25. 
    Le Naour F., B.F., Misek D. E., BresChot C., Hanash S. M., and Beretta L, (2002), “A Distinct Repertoire of Autoantibodies in Hepatocellular Carcinoma Identified by Proteomic Analysis”, Mole & Cell Prot, 1, PP.197–203.
    
26. 
    Liebler D.C (2002), “Introduction to Proteomics”, Humana Press Inc, New Jersey.
    
27. 
    Lupberger J., H.E. (2007), “Hepatitis B virus-induced oncogenesis”, World J Gast, PP. 74-81.
    
28. 
    Mai.T.N,. Thai. T. H. (2009), “Proteomic analysis of liver tissue from some animals in the region exposed to dioxin at Ma Da area, Dong Nai province”, VNU Jounal of Science, Nat,Sci & Tech, 24, PP. 13-19.
    
29. 
    Maria Pleguezuelo, Laura M Lopez-Sanchez, Antonio Rodriguez-Ariza, Jose L Montero, Javier Briceno, Rubenciria, and Jordi Muntane (2010), “Proteomic analysis for developing new biomarkers of hepatocellular carcinoma”, World J Hepatol, 2 (3), PP. 127-135.
    
30. 
    Mary A. C and Laura J. F, (2005), “GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma”, J Hepat, 43 (6), PP. 1007-1012.
    
31. 
    Mazzanti R., L. Gramantieri, and L. Bolondi (2008), “Hepatocellular carcinoma: Epidemiology and clinical aspects”, Molec Asp Med, 29(1–2), PP. 130–143.
    
32. 
    M. Hollstein, B. Shomer, M. Greenblatt, T. Soussi, E. Hovig, R. Montesano & C. C. Harris (1996), “Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation”. Nucl Aci Res, 24, PP. 141-156
    
33. 
    M. Hsiao, J. Low, E. Dorn, D. Ku, P. Pattengale, J. Yeargin (1994). “Gain of function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness”. Am J Pathol (145), PP. 402-414.
    
34. 
    M. S. Greenblatt, W. P. Bennett, M. C. Hollstein & C. C. Harris (1994), “Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis”, Cancer Res , 54, PP. 4855-4878.
    
35. 
    Mohammad Hossein Somi Md Assistant Professor (2005), “Hepatocellular carcinoma”, Hepat Hepat,5(3),PP. 65-67.
    
36. 
    Nikolova M. S., D.O.M.G., Medical Faculty, Medical University Sofia, (2007), “Molecular pathogenesis of Hepatocellular carcinoma ”, Bal J Med Genetics, 10 (1), PP. 15-22.
    
37. 
    Paradis V., B.P. (2007), “In the new area of noninvasive markers of hepatocellular carcinoma In the new area of noninvasive markers of hepatocellular carcinoma”, J Hepat, 46, PP.11-49.
    
38. 
    Pastorino JG, Shulga N, Hoek JB. (2002), “Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis”, J Biol Chem, 277, PP. 7610–7618
    
39. 
    Polanski M., A.N.L. (2006), “A List of Candidate Cancer Biomarkers for Targeted Proteomics”, Bio Ins, 1, PP.1-48.
    
40. 
    Qin L.X., T.Z.Y. (2002), "The Prognotics molecular markers in hepatocellular carcinoma", World J Gast, 8(3), PP. 385-392.
    
41. 
    Sun W., X.B., Sun Y, Du X., Lu M., Hao C., Lu Z., Mi W., Wu S., Wei H., Gao X., Zhu Y., Jiang Y., Qian X., and He F, (2007), “Proteome Analysis of Hepatocellular Carcinoma by Two-dimensional Difference Gel Electrophoresis”, Mole & Cell Pro, 6, PP.1798–1808.
    
42. 
    Thai T. H., Huong. T. T. T. (2005), “Plasma proteomic analysis of acute myeloid Leukemia patients”, VNU, Journal of science, Nat.,Sci., & Tech, 4, PP. 54-60.
    
43. 
    William Cs Cho (2007), "Contribution of oncoproteomics to cancer biomarker discovery", Mole Cancer, 10, PP. 6-25.
    
44. 
    Wong C. H., C.S.K.P., Chan H.L.Y., Tsui S.K.W. (2006), “The Molecular Diagnosis of Hepatitis B Virus-Associated Hepatocellular Carcinoma”, Clin Lab Sci, 43(41), PP.69-101.
    
45. 
    Rowan. S., Ludwig.R. L. , Haupt.Y. , Bates.S. , Lux.X. , Oren.M, 1996 “Specific loss of apoptotic but not cell cycle arrest function in human tumour derived p53 mutant”, EMBO J, 15, PP. 827-838.
    

46. 
    http://biol.lf1.cuni.cz/ucebnice/en/proteomics.htm (13/11/2010)
    
47. 
    http://.cancer.org/docroot/CRI/CRI_2_1x.asp?dt=25Cancer.org2 (11/10/2010)
    
48. 
    http://en.wikipedia.org/wiki/Hexokinase (02/12/2010)
    
49. 
    http://en.wikipedia.org/wiki/Major_vault_protein (14/11/2010)
    
50. 
    http://en.wikipedia.org/wiki/Heat_shock_protein#Cancer_vaccine_adjuvant (23/11/2010)
    
51. 
    http://www.uniprot.org/uniprot/?query (08/10/2010)
    
52. 
    http://www.medicinenet.com/script/main/art?articlekey=104954 (14/09/2010)
    
53. 
    http://www.siteman.wustl.edu/PDQ.aspx?id=662&xml=CDR256491.xml (27/11/2010)
    
54. 
    http://www.antigenics.com/products/tech/hsp/ (24/10/2010)
    
55. 
    http://www.bioscience.org/2005/v10/af/1736/figures.htm (15/12/2010)
    
56. 
    http://www.bioscience.org/1997/v2/d/soehnge/d538-551.htm (29/10/2010)
    
57. 
    http://www.hopkinsmedicine.org/liver_tumor_center/conditions/cancerous_liver_tumors/hepatocellular_carcinoma.html (12/12/2010)
    
58. 
    http://www.nature.com/nrm/journal/v9/n4/full/nrm2384.html (12/12/2010)
    
59. 
    http://mct.aacrjournals.org/content/6/9/2554.abstract (26/09/2010)